Panacea Life Sciences Holdings, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)
Panacea Life Sciences Holdings, Inc. (PLSH) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) of $0 for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-04-23.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease · last filed 2021-04-23
- Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2019-12-31 was $0.00.
- Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2019-09-30 was $0.00.
- Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2019-06-30 was $0.00.
- Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2019-03-31 was -$3.21M.
- Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2020 was $0.00.
- Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2019 was -$3.21M.
- Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2018 was -$90.86K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 12 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K/A · filed 2021-04-23 | ||||
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-23 | $0.00 derived: sum of 2 quarters · filed 2021-04-23 | $0.00 derived: sum of 3 quarters · filed 2021-04-23 | -$3.21M 10-K/A · filed 2021-04-23 | -$3.40M 10-K · filed 2020-05-22 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | -$3.21M 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$3.21M 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | -$3.21M 10-Q · filed 2019-05-20 | ||||
| 2018-12-31 | -$90.86K 10-K · filed 2020-05-22 |